Frank Voisin is the author of the popular value focused website Frankly Speaking, found at http://www.FrankVoisin.com The following is a reader submission on PhotoMedex (NASDAQ:PHMD). Frank’s Disclosure: No position in any of the securities mentioned. ———————————- IS PHOTOMEDEX POISED FOR A SHORT SQUEEZE? SUMMARY Photomedex (“PHMD”) is a heavily shorted stock which we think is a compelling long, especially considering the possibility of a major short squeeze. Despite the large short position (25%+ of float, ~20% cost to borrow), PHMD is actually an undervalued (5.1x 2013E Adj EBITDA) , unlevered (20% of its market cap is in net cash), growing (revenue and EBITDA should increase organically in 2013), high free cash flow company (D&A significantly higher than maintenance capex, an nol reduces cash taxes and non-recurring items distort LTM results) with a buyback waiting to be used (the company has been restricted from repurchasing stock for many months but the window reopens in May) and a management team which owns ~30% of the company and is incentivized to create shareholder value. BUSINESS DESCRIPTION The current PHMD was formed in December 2011 with the merger of Radiancy (which makes a number of products including the no!no!) with Photomedex (which has a strong proprietary consumer
Read More »











